| 1. |
- Aad, G., et al.
(författare)
-
- 2015
-
Ingår i: Physical Review D (Particles, Fields, Gravitation and Cosmology). - 1550-2368 .- 1550-7998. ; 91:11, s. 112011-
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Aad, G., et al.
(författare)
-
- 2015
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Ahmad, Shakeel, et al.
(författare)
-
Two-Tone PLL for on-Chip IP3 Test
- 2010
-
Ingår i: Swedish System-on-Chip Conference.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Ahmad, Tausif, et al.
(författare)
-
Controllable phytosynthesis of gold nanoparticles and investigation of their size and morphology-dependent photocatalytic activity under visible light
- 2020
-
Ingår i: Journal of Photochemistry and Photobiology A. - : Elsevier. - 1010-6030 .- 1873-2666. ; 392, s. 1-11
-
Tidskriftsartikel (refereegranskat)abstract
- Plants mediated synthesis of gold nanoparticles (AuNPs) containing desired characteristics for their suitable potential applications has been a challenging task, which is causing a major hindrance towards its commercialization. Therefore, herein phytosynthesis of AuNPs with required size and morphology has been achieved through manipulating the reaction conditions including reaction temperature and volume of Elaeis guineensis leaves (EGL) extract. Furthermore, photocatalytic potential of EGL mediated AuNPs having different size and shape has also been explored for the removal of methylene blue (MB) under visible light irradiation. The reaction temperature and volume of EGL strongly influenced the size and morphology of AuNPs, which are directly associated with the photocatalytic activities. The experimental results revealed that predominantly spherical and ultra-smaller size AuNPs with particle size of 16.26 ± 5.84 nm, formed at 70 °C showed the highest removal efficiency up to 92.55 % in 60 min. This highest photocatalytic activity of AuNPs could be attributed to the availability of higher number of low-coordinated gold (Au) atoms in the MB aqueous solution, which might have boosted the adsorption of the MB on the surface of particles and accelerated the degradation phenomenon. The proposed photocatalytic degradation mechanism of AuNPs for MB was also explained. The highly photoactive EGL mediated AuNPs with controllable morphology and size could be an advance step in future in chemical and biomedical applications.
|
|
| 5. |
|
|
| 6. |
- Joensuu, Heikki, et al.
(författare)
-
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
- 2014
-
Ingår i: Acta Oncologica. - : Informa Healthcare. - 0284-186X .- 1651-226X. ; 53:2, s. 186-194
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundLittle information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab.Patients and methodsOne thousand and five hundred patients with early breast cancer were entered to the Finland Capecitabine trial (FinXX) between January 2004 and May 2007, and were randomly assigned to receive either three cycles of adjuvant TX (docetaxel, capecitabine) followed by three cycles of CEX (cyclophosphamide, epirubicin, capecitabine; TX-CEX) or three cycles of docetaxel followed by three cycles of CEF (cyclophosphamide, epirubicin, fluorouracil; T-CEF). The primary endpoint was recurrence-free survival (RFS). The study protocol was amended in May 2005 while study accrual was ongoing to allow adjuvant trastuzumab for patients with HER2-positive cancer. Of the 284 patients with HER2-positive cancer accrued to FinXX, 176 (62.0%) received trastuzumab after amending the study protocol, 131 for 12 months and 45 for nine weeks. The median follow-up time was 6.7 years.ResultsPatients with HER2-positive cancer who received trastuzumab had better RFS than those who did not (five-year RFS 89.2% vs. 75.9%; HR 0.41, 95% CI 0.23 -0.72; p = 0.001). Patients treated with trastuzumab for 12 months or nine weeks had similar RFS. There was no significant interaction between trastuzumab administration and the type of chemotherapy. Four (2.3%) patients treated with trastuzumab had heart failure or left ventricular dysfunction, three of these received capecitabine.ConclusionAdjuvant trastuzumab improves RFS of patients treated with TX-CEX or T-CEF. Few patients had cardiac failure.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Adare, A., et al.
(författare)
-
Pseudorapidity Dependence of Particle Production and Elliptic Flow in Asymmetric Nuclear Collisions of p+Al, p+Au, d+Au, and 3He+Au at √sNN=200 GeV
- 2018
-
Ingår i: Physical Review Letters. - 1079-7114. ; 121
-
Tidskriftsartikel (refereegranskat)abstract
- Asymmetric nuclear collisions of p+Al, p+Au, d+Au, and 3He+Au at √sNN=200 GeV provide an excellent laboratory for understanding particle production, as well as exploring interactions among these particles after their initial creation in the collision. We present measurements of charged hadron production dNch/dη in all such collision systems over a broad pseudorapidity range and as a function of collision multiplicity. A simple wounded quark model is remarkably successful at describing the full data set. We also measure the elliptic flow v2 over a similarly broad pseudorapidity range. These measurements provide key constraints on models of particle emission and their translation into flow.
|
|
| 10. |
|
|
